US75955J4022
US75955J4022
Relmada Therapeutics, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | -- | -- | -- |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 59.100.200 | 83.891.036 | 29.6% | |
| Operating Income | -59.100.200 | -83.891.036 | 29.6% |
| Pretax Income | -57.385.163 | -79.979.354 | 28.3% |
| Net Income Common Stockholders | -57.385.163 | -79.979.354 | 28.3% |
| -- | -- | -- | |
| -- | -- | -- |